靶向α治疗在转移性神经内分泌肿瘤中的疗效与安全性:一项Meta分析
本Meta分析纳入7项研究共162例转移性神经内分泌肿瘤患者,评估靶向α治疗(TAT)的疗效与毒性。汇总客观缓解率(ORR)为49.5%(95%CI 41.7%-57.4%),疾病控制率(DCR)为87.0%(95%CI 72.1%-96.8%),3-4级血液学与肾脏不良事件发生率分别为2.1%(95%CI 0.5%-5.5%)和3.4%(95%CI 1.2%-7.3%)。作者认为TAT是转移性NET的有效治疗选择。
要点
- 7项研究162例转移性NET患者,TAT汇总ORR 49.5%、DCR 87.0%。
- 3-4级血液学毒性2.1%、肾脏毒性3.4%,发生率低。
- 亚组分析示ORR 46.6%-57.1%、DCR 82.0%-91.5%,疗效一致。
核心结论
- TAT是转移性NET的有效治疗,显示出较高的疾病控制率和缓解率且毒性最低。
- 这些发现提示TAT是转移性NET患者可行的治疗替代选择。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library和CINAHL数据库,纳入7项研究共162例转移性NET患者进行Meta分析。
- 分析汇总ORR和DCR比例以评估疗效,评估3级或4级严重血液学和肾脏不良事件发生率以评估毒性,并进行亚组分析识别影响治疗结局的因素。
主要发现
- TAT达到ORR 49.5%(95%CI 41.7%-57.4%)和DCR 87.0%(95%CI 72.1%-96.8%)。
- 血液学毒性发生率为2.1%(95%CI 0.5%-5.5%),肾脏毒性发生率为3.4%(95%CI 1.2%-7.3%)。
- 亚组分析显示在不同变量(包括既往177Lu-based肽受体放射性核素治疗、225Ac-based TAT、无放射增敏剂及疗效评估方法)中疗效一致,ORR范围为46.6%至57.1%,DCR范围为82.0%至91.5%。
关键数值与推荐
- 疗效评估采用汇总ORR和DCR比例。
- 毒性评估采用3级或4级严重血液学和肾脏不良事件发生率。
- 亚组分析变量包括既往177Lu-based肽受体放射性核素治疗、225Ac-based TAT、无放射增敏剂及疗效评估方法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite the effectiveness of 177 Lu-based peptide receptor radionuclide therapy in treating metastatic neuroendocrine tumors (NETs), disease progression posttreatment remains a significant challenge. Targeted alpha therapy (TAT) has emerged as a promising option for patients experiencing such progression. This study aims to assess the therapeutic efficiency and toxicity of TAT in patients with metastatic NET through a meta-analysis. PATIENTS AND METHODS: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, and CINAHL using relevant keywords. The analysis focused on the pooled proportions of objective response rate (ORR) and disease control rate (DCR) to determine therapeutic efficiency. We also evaluated the incidence of serious hematologic and renal adverse events (grade 3 or 4) to assess toxicity. A subgroup analysis was performed to identify factors influencing therapeutic outcomes. RESULTS: Our meta-analysis included 7 studies comprising 162 patients. The results showed that TAT achieved ORR of 49.5% (95% confidence interval [CI]: 41.7%-57.4%) and DCR of 87.0% (95% CI: 72.1%-96.8%). The incidences of hematologic and renal toxicities were low, at 2.1% (95% CI: 0.5%-5.5%) and 3.4% (95% CI: 1.2%-7.3%), respectively. Subgroup analysis indicated consistent therapeutic efficiency across different variables, including prior 177 Lu-based peptide receptor radionuclide therapy treatment, 225 Ac-based TAT, absence of radiosensitizer, and methods of response evaluation, with ORR ranging from 46.6% to 57.1% and DCR from 82.0% to 91.5%. CONCLUSIONS: TAT is an effective treatment for metastatic NET, demonstrating substantial disease control and response rates with minimal toxicity. These findings suggest that TAT is a viable therapeutic alternative for patients with metastatic NET.
引用
- Lee DY, Kim YI. Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med. 2024. PMID: 39169519. doi:10.1097/RLU.0000000000005404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。